Recruiting PHASE1/PHASE2 INTERVENTIONAL 1-arm NCT06253130

A First-in-human Study of PARP1 Selective Inhibitor, IMP1734, in Participants With Advanced Solid Tumors

A First-in-human, Phase 1/2, Open-label, Multi-center, Dose-escalation, Dose-optimization, and Dose-expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Anti-tumor Activity of PARP1 Selective Inhibitor, IMP1734, as Monotherapy in Patients With Advanced Solid Tumors

Sponsor: Eikon Therapeutics

Conditions Advanced Solid Tumor

Interventions IMP1734

Updated 10 times since 2024 Last updated: Nov 24, 2025 Started: Dec 11, 2023 Primary completion: Feb 1, 2026 Completion: Dec 1, 2026

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Listed as NCT06253130, this PHASE1/PHASE2 trial focuses on Advanced Solid Tumor and remains actively recruiting participants. Sponsored by Eikon Therapeutics, it has been updated 10 times since 2023, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

Change History

10 versions recorded

Jan 2026 — Present [monthly]

Recruiting PHASE1/PHASE2
Sep 2025 — Jan 2026 [monthly]

Recruiting PHASE1/PHASE2
May 2025 — Sep 2025 [monthly]

Recruiting PHASE1/PHASE2
Apr 2025 — May 2025 [monthly]

Recruiting PHASE1/PHASE2
Nov 2024 — Apr 2025 [monthly]

Recruiting PHASE1/PHASE2

▶ Show 5 earlier versions

Oct 2024 — Nov 2024 [monthly]

Recruiting PHASE1/PHASE2
Sep 2024 — Oct 2024 [monthly]

Recruiting PHASE1/PHASE2
Jul 2024 — Sep 2024 [monthly]

Recruiting PHASE1/PHASE2

Phase: PHASE1_PHASE2 → PHASE1/PHASE2
May 2024 — Jul 2024 [monthly]

Recruiting PHASE1_PHASE2
Mar 2024 — May 2024 [monthly]

Recruiting PHASE1_PHASE2

First recorded

Dec 2023

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Eikon Therapeutics
Impact Therapeutics, Inc.

Data source: Eikon Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

Ann Arbor, United States , Barcelona, Spain , Caen, France , Celebration, United States , Charleston, United States , Chongqing, China , Copenhagen, Denmark , Denver, United States , Detroit, United States , Edmonton, Canada and 37 more locations